Skip to main content
. 2022 Aug 9;23(9):3822–3830. doi: 10.1021/acs.biomac.2c00671

Figure 3.

Figure 3

Hit compounds reduce hypoxia-induced blood flow impairment. We treated RBC suspensions at 25% hematocrit from 7 individuals with SCD (genotype HbSS) with 500 μM of our hit compounds or voxelotor (positive control) and quantified the flow in our microfluidic platform under well-defined oxygen tensions. (A) Representative image of blood flowing in microfluidic device with overlay of green arrows representing the velocities of features between frames using the Kanade–Lucas–Tomasi algorithm. (B) Area under velocity response curve (AUC) comparison among treated samples compared to the vehicle control. (C) Deceleration rate comparison among treated samples compared to the vehicle control. All statistics were performed using a one-tailed Wilcoxon signed rank test, α = 0.05, *p-value < 0.05, **p-value < 0.01.